Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521685 | 1.00 | MKNK1 (1.00) | MKNK1FYN | |
| SCHEMBL16429515 | 0.90 | MKNK1 (0.82) | MKNK1FYN | |
| SCHEMBL16331216 | 0.86 | MKNK1 (0.76) | MKNK1FYN | |
| SCHEMBL1053056 | 0.86 | MKNK1 (0.75) | MKNK1FYN | |
| SCHEMBL2940432 | 0.86 | MKNK1 (0.82) | MKNK1FYN | |
| SCHEMBL13859380 | 0.83 | MKNK1 (0.77) | MKNK1FYN | |
| SCHEMBL2947494 | 0.82 | MKNK1 (0.75) | MKNK1FYN | |
| SCHEMBL13859442 | 0.81 | MKNK1 (0.74) | MKNK1FYN | |
| SCHEMBL16117410 | 0.80 | MKNK1 (0.70) | MKNK1FYN | |
| SCHEMBL13859103 | 0.80 | MKNK1 (0.73) | MKNK1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| EP-3347462-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | Lau, Warren C. (US) | 2018-07-18 | — | — | EP | claimed |
| WO-2017044623-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | LAU WARREN C (US) | 2017-03-16 | — | — | WO | claimed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014076162-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| WO-2012175591-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | MKNK1 163/4885FYN 1/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | MKNK1 163/4885FYN 1/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | MKNK1 163/4885FYN 1/4885 |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | MKNK1 144/4885FYN 421/4885 |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | MKNK1 3763/4885FYN 2261/4885 |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | MKNK1 163/4885FYN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.